BeyondSpring (NASDAQ:BYSI) Posts Quarterly Earnings Results, Beats Expectations By $0.49 EPS

BeyondSpring (NASDAQ:BYSI) issued its earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.49, FiscalAI reports.

BeyondSpring Stock Down 1.7%

BYSI stock traded down $0.03 during mid-day trading on Friday, reaching $1.45. 12,268 shares of the company traded hands, compared to its average volume of 23,270. The stock has a market cap of $59.42 million, a price-to-earnings ratio of -9.63 and a beta of 0.41. BeyondSpring has a fifty-two week low of $1.21 and a fifty-two week high of $3.44. The firm’s 50 day moving average price is $1.62 and its 200 day moving average price is $1.70.

Hedge Funds Weigh In On BeyondSpring

An institutional investor recently raised its position in BeyondSpring stock. Geode Capital Management LLC raised its stake in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 951.4% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 256,212 shares of the company’s stock after purchasing an additional 231,844 shares during the period. Geode Capital Management LLC owned approximately 0.64% of BeyondSpring worth $603,000 as of its most recent SEC filing. 40.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of BeyondSpring in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, BeyondSpring currently has an average rating of “Sell”.

BeyondSpring Company Profile

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.